Soligenix, Inc. Common Stock (NASDAQ: SNGX) is having an incredible day in the market today, and for good reason. The company announced the coming presentation of clinical data, exciting investors and leading to gains in the stock. Of course, our partners at Trade Ideas were the first to alert us to the movement. At the moment (10:29), SNGX is trading at $4.42 per share after a gain of $1.85 per share (71.98%) thus far today.

SNGX Gains On Coming Presentation

As mentioned above, Soligenix is off to an incredibly strong day in the market today after announcing that it will be presenting results from the development program surrounding its ricin toxin vaccine, RiVax(TM), relatively soon. The data will be presented at the 20th Annual Conference on Vaccine Research, which will be held from April 24th through April 26th. The company is expecting that the findings will facilitate potential FDA approval of the RiVax(TM) vaccine, representing a significant step forward in the understanding of ricin toxin immunology.

What We'll Be Watching For Ahead

Moving forward, the CNA Finance team will be keeping a close eye on SGNX. In particular, we're interested in following the company through the process of getting RiVax approved and whether or not an approval will actually happen. Nonetheless, we'll continue to follow the story closely and bring the news to you as it breaks!

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!
* indicates required
Hey everyone, I'm Joshua Rodriguez. I'm the founder of CNA Finance as well as several other sites. If you'd like to connect with me, follow me on or Twitter! I'd love to see ya there. Also, if you're looking for top quality content for your blog, news outlet, or any other website for that matter, please reach out to me at Info@CNAFin.com! Legal Disclaimer - CNA Finance is NOT an investment advisor. All investment decisions should be well thought out and made with the help of a an investment advisor. For our full legal disclaimer, please scroll to the bottom right of this page.

NO COMMENTS

Leave a Reply